The difference between molecularly targeted therapy and biologic therapy

Biotechnology is an emerging oncology technology with significant efficacy. The technology has gone through five stages of development, namely lymphokine-activated killer cell (LAK) stage, tumor-infiltrating lymphocyte (TIL) stage, cytokine-induced killer cell (CIK) stage, dendritic cell (DC) stage, and biclonal immune cell (DC-CIK) stage. With the development and gradual maturity of the technology, it has been widely used in clinical practice.

Molecular targeting**The so-called molecular targeting** is at the cellular molecular level, targeting the cancer-causing site that has been identified (the site can be a protein molecule inside the tumor cell, or a gene fragment), to design the corresponding **drug, the drug will specifically select the carcinogenic site to combine and act when it enters the body, so that the tumor cells will die specifically, and will not affect the normal tissue cells around the tumor, so molecular targeting** is also known as "biological missile".

Biology is a broad concept that involves all methods of using biological macromolecules, and there are many types. If you divide it into non-cellular** and cellular** from the mode of operation. Bio** is the fourth type of cancer developed after surgery, radiotherapy and chemotherapy, which uses and stimulates the body's immune response to fight, inhibit and kill cancer cells.

Molecular targeting is at the molecular level, and biological targeting is at the cellular level.

Analysis: Hello! This is a **method**, but this kind of ** is very expensive. Guidance: Molecular biological targeting**, before taking the drug, it is necessary to check whether the corresponding gene is expressed, if it is not expressed, this ** is not effective.

After targeted cancer drugs**, the survival time of patients varies from person to person. Everyone responds differently to cancer, including targeting. Some people have a good effect, some people have a poor effect, and before using targeted drugs, genetic testing must be done first.

If there is a sensitive mutation in genetic testing, the corresponding targeted drugs are used, the effect is better, and the control of the tumor can reach the ideal degree. If the tumor does not grow and even shrinks, the damage to the human body is very small. At present, all targeted drugs have the problem of drug resistance, and the length of drug resistance depends on the reaction of the drug and the human body, the resistance time of targeted drugs is about 11 months, and some of the short time can be 1-2 months, 2-3 months, and drug resistance also appears, and the longer time can be effective for several years and even achieve long-term tumor survival.

Therefore, the degree of benefit and survival time that targeted drugs can bring to patients after use depends on the specific situation. However, there are benefits to using targeted drugs. As the tumor gets smaller, the patient feels comfortable and is able to live longer.

After the tumor becomes smaller, there is a chance for follow-up, such as surgery, chemotherapy or others, to provide time. It would be more desirable for patients taking targeted ** plus Chinese medicine**.

Targeting** is at the cellular molecular level, targeting the oncogenic site that has been identified (the site can be a protein molecule inside the tumor cell, or a gene fragment) to design the corresponding ** drug, the drug will specifically select the carcinogenic site to combine and act when entering the body, so that the tumor cells will die specifically, and will not affect the normal tissue cells around the tumor, so molecular targeting** is also known as "biological missile".

IntroductionTargeting** refers to a method that uses standardized biomarkers to identify the presence of a disease-specific gene or gene profile that controls tumor growth, thereby identifying a specific target. Some tumors are formed as a result of and depend on the activation of a single consistent oncogene, a phenomenon known as oncogene dependence. The identification of drug-worthy oncogenic drivers has created the possibility of using highly effective interventions, including KRAS, EGFR, EML4-ALK, etc.

For non-small cell lung cancer (NSCLC) with identified pathogenic genes, individualized** targeted drugs have targeted efficacy, including gefitinib, erlotinib for EGFR, crizotinib for EML4-ALK, etc.

With the continuous development of medical science, nuclear gene professionals have conducted in-depth research on the causes of malignant tumors, the mechanism of gene carcinogenes has gradually become clear, and high-end biotechnology based on oncogenes has been continuously applied in medical clinics.

With the help of the continuous progress of modern scientific and technological means, people's understanding of tumors has penetrated to the cellular, molecular and genetic levels, and the mastery of tumor diagnosis and technology has no longer stayed at the level of site and organ morphology, but combined with morphological and functional changes, and gradually developed in the direction of cytology, molecular biology and even genomics classification diagnosis and development. At the same time, with the rapid development of materials science, computer technology, and digital imaging technology, the combination of biomedical engineering technology and clinical oncology diagnosis and treatment technology is becoming more and more close, resulting in the birth of many tumor targeting technologies. With the joint efforts of multidisciplinary colleagues in oncology at home and abroad, tumor targeting technology has been continuously promoted, and the efficacy has been continuously improved.

Keeping pace with the times, since its establishment in 2004, the Tumor Targeting Technology Branch of the Chinese Society of Biomedical Engineering has continuously summarized and formulated the operating specifications of tumor targeting technology by holding many domestic and foreign academic conferences, multi-center collaboration and multidisciplinary cooperation, so that the concept of tumor individualization, targeting and synthesis has been continuously recognized by the academic community at home and abroad.

However, in general, the target is not mature enough in the practical application in China, and the role it can play is very limited, and it is difficult to accurately realize more theoretical research, so there is still a lot of room for improvement in this aspect of research.

Q: What is targeting and what are its benefits?

Sun: The so-called targeting** means that according to the different specific sites of the tumor, anti-tumor drugs act on it in a targeted manner to kill tumor cells, and have little impact on normal tissues. This is currently the most ideal mode.

Our major oncology centers and specialized hospitals in China can detect some targets of breast cancer, such as ER PR, HER2 receptor, TP DPD enzyme, etc., and target them according to the test results**. Such ** is more personalized, and the results are usually satisfactory. And due to the continuous emergence of a new generation of drugs, while being effective, the adverse reactions to patients have also been greatly improved.

Targeting** is actually drug inhibition and blockade of cancer driver genes, and then kill cancer cells. Therefore, it is necessary to do genetic testing before taking it.

If the test result is positive, especially if the gene mutation in the sensitive part is used, then with the corresponding targeted drugs, the effective rate is basically more than 90%.

If all of them are negative, it may indicate that there is no targeted drug with particularly good effect, and the effective rate of taking targeted drugs is less than 10%, so it will not be recommended as a preferred regimen.